About

Science

Pipeline

Investor Information

Contact Us

Investor Information

Investor Information

Press Releases

Jan 24, 2019 7:30 AM EST Can-Fite BioPharma CEO Letter to Shareholders
Jan 18, 2019 8:00 AM EST Can-Fite BioPharma Announces Registered Direct Offering
Jan 8, 2019 8:00 AM EST Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
Jan 3, 2019 8:02 AM EST Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
Dec 10, 2018 7:00 AM EST Can-Fite Enters Into Collaboration Agreement to Explore Namodenoson’s Anti-NASH Effect With Icahn School of Medicine at Mount Sinai in NYC
Nov 30, 2018 7:00 AM EST Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
Nov 20, 2018 7:00 AM EST Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
Oct 31, 2018 7:00 AM EDT Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Oct 25, 2018 7:00 AM EDT Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
Oct 18, 2018 7:00 AM EDT Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018

<< Previous
1...
5
6
7
8
9
10
11
12
13
14
...30
Next >>

Show All